Moclobemide enhances aversively motivated learning and memory in rats

Polish Journal of Pharmacology

Volumn 51, Issue 6, 1999, Pages 497-503

  Frank, Marek ^a   Braszko, Jan J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Depression; Memory; Moclobemide; Rat

Indexed keywords

MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVERSION; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; LEARNING; MALE; MEMORY; NONHUMAN; PASSIVE AVOIDANCE; PSYCHOMOTOR ACTIVITY; RAT; RECOGNITION; TRANQUILIZING ACTIVITY;

ANIMALS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; RATS; RATS, WISTAR;

EID: 0033373830     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ader R., Weijnen J. A. M. W., Moleman P.: Retention of a passive avoidance responses as a function of the intensity and duration of electric shock. Psychon. Sci., 1972, 26, 125-129.
2. Allain H., Lieury A., Brunet-Bourgin F.: Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology, 1992, 106, 856-861.
3. Amado-Boccara I., Gougolis N., Poirier Littre M. F., Galinowski A., Loo H.: Effects of antidepressants on cognitive functions: a review. Neurosci. Biobehav. Rev., 1995, 19, 479-493.
4. Anand R., Wesnes K. A.: Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. Adv. Neurol., 1990, 51, 261-268.
5. Angst J.: The efficacy of moclobemide (1977-1994). Farmakoter. Psychiat. Neurol., 1995, 1, 31-48.
6. Baldwin D., Rudge S.: Tolerability of moclobemide. Rev. Contemp. Pharmacother., 1994, 5, 57-65.
7. Berlin I., Zimmer R., Thiede H-M., Payan C., Hergueta T., Robin L., Puech A. J.: Comparison of the monoamine oxidase inhibiting properties of two reversible and selectivee monoamine oxidase-A inhibitors moclobemide and taloxatone, and assessment of their effect on psychometric performance in healthy subjects. Brit. J. Clin. Pharmacol., 1990, 30, 805-816.
8. Braszko J. J., Kułakowska A., Wiśniewski K.: Angiotensin II and its 3-7 fragment improve recognition but not spatial memory in rats. Brain Res. Bull., 1995, 37, 627-631.
9. Braszko J. J., Wiśniewski K., Kupryszewski G., Witczuk B.: Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs cognitive behaviour. Behav. Brain Res., 1987, 25, 195-203.
10. Da Prada M., Kettler R., Keller H. H., Burkard W., Muggli-Maniglio D., Haefely W. E.: Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase A. J. Pharmacol. Exp. Ther., 1989, 248, 400-414.
11. Da Prada M., Pieri L., Cesura A. M.: The pharmacology of moclobemide. Rev. Contemp. Pharmacother., 1994, 5, 1-18.
12. Ennaceur A., Meliani K.: A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs nonspatial working memory. Behav. Brain Res., 1992, 51, 83-92.
13. Fitton A., Faulds D., Goa K. L.: Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs, 1992, 43, 561-596.
14. Fulton B., Benfield P.: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs, 1996, 52, 450-474.
15. Haefely W., Burkard W. P., Cesura A. M., Colzi A., Kettler R., Lorez H. P., Martin R., Moreau J. L., Richards J. G., Schaffner. R. et al.: Pharmacology of moclobemide. Clin. Neuropharmacol., 1993, 16, S8-S18.
16. Haefely W., Burkard W. P., Cesura A. M., Kettler R., Lorez H. P., Martin J. R., Richards J. G., Scherschlicht R., Da Prada M.: Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology, 1992, 106 Suppl., S6-14.
17. Hindmarch I., Kerr J.: Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology, 1992, 106, S49-S55.
18. Johnson J., Sims R.: Differential diagnosis of dementia, delirium, and depression. Implications for drug therapy. Drug. Aging, 1994, 5, 431-445.
19. Kostowski W.: Mechanism of action and pharmacology of new drugs belonging to the group of monoamine oxidase inhibitors (Polish). Farmakoter. Psychiat. Neurol., 1995, 1, 3-10.
20. Mashkowskii M. D., Andreyeva V., Parshin A., Golovina S. M.: Antiamnestic properties of some antidepresants. Farmakol. Toksikol., 1991, 54, 5, 4-5.
21. Nowakowska E., Chodera A., Kus K., Rybakowski J.: Anxiolytic and memory improving effects of moclobemide., Arzneim.-Forsch. - Drug Res., 1998, 48 (I), 625-628.
22. Pellow S., Chopin P., Briley M.: Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth., 1985, 14, 149-167.
23. Priest R. G., Schmid-Burgk W.: Moclobemide in the treatment of depression. Rev. Contemp. Pharmacother., 1994, 5, 35-44.
24. Riedel W. J., van Praag H. M.: Avoiding and managing anticholinergic effects of antidepressants., CNS Drugs, 1995, 3, 245-259.
25. Thompson P. J.: Antidepressants and memory: a review. Hum. Psychopharmacol. Clin. Exp., 1991, 6, 79-90.
26. Wesnes K. A., Simpson P. M., Christmas L., Anand R., McClelland G. R.: The effects of moclobemide on cognition. J. Neural Transm., Suppl., 1989, 28, 91-102.